IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

Interna	ational A	Application No.	:	PCT/EP2004/005547
Interna	ational I	Filing Date	:	May 24, 2004
Priorit	y Date(s) Claimed	:	June 16, 2003
Applic	cant(s) (DO/EO/US)	:	Timo HEINRICH et al.
Title:	INDO	LE DERIVATIVES A	S SEROTONII	N REUPTAKE INHIBITORS
<u>INFO</u>	RMAT	ION DISCLOSURE	STATEMENT	T UNDER 37 CFR §§ 1.56, 1.97 and 1.98
P.O. B	ox 145	r for Patents 0 A 22313-1450		
Sir:				
and 1.	This in 98 as fo		tatement is mad	le in accordance with 37 C.F.R. §§ 1.56, 1.97
<u>Timin</u>	g and F	ees		
\boxtimes		37 C.F.R. § 1.97(b), sure statement is filed:	no fee or stater	ment is required for filing this information
		within three months of under § 1.53(d);	of the filing date	e of a national application other than a CPA
		within three months application; OR	of the actual f	filing date of the national phase of a PCT
	\boxtimes	before the mailing of RCE).	a first substanti	ive office action (including after filing of an
		37 C.F.R. § 1.97(c), the d in 37 C.F.R. § 1.97		disclosure statement is filed after the periods the mailing date of:
		a final rejection unde	r 37 C.F.R. 1.1	13;

termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

		is acco	empanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a r	notice of allowance under 37 C.F.R. § 1.311;
	AND	is filed o	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	Materia	<u>ls</u>	
		ancest	or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	\boxtimes	_	s of materials listed but not attached were cited in an international search dated August 19, 2004.
		Not re	quired by 37 CFR § 1.98.
		Copies	s of the materials listed are attached (except for the foregoing).

Non-E	inglish I	Language References
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	\boxtimes	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art
		O = non-written disclosure
		P = intercalated document
		T = document cited to understand the theory or principle underlying the invention
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
		D = cited in the application
		L = cited for another reason
		& = publication of member of same patent family
	\boxtimes	Translation of other relevant information on foreign search report
		In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.
Other	<u>Informa</u>	<u>ition</u>
Payme	ent of Fe	ees Due (If Any):
		ck for \$ covering the fee identified above is attached.
	Ache	or for \$\psi covering the fee identified above is attached.
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelang, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3099

Date: December 15, 2005

AJZ:aap

K:\Merck\3000 - 3999\3099\Information Disclosure Statement.doc

IAP9 Rac'd PCT/PTO 15 DEC 2003

Please type e plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademerk Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons ere required to respond to e collection of information unless it contains e valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number PCT/EP2004/005547 INFORMATION DISCLOSURE December 15, 2005 STATEMENT BY APPLICANT First Nemed Inventor Timo HEINRICH et al. Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned Sheet of MERCK-3099 Attorney Docket Number

	U.S. PATENT DOCUMENTS						
Exeminer Initials *	Cite No.1	U.S. Petent Doc	Kind Code ² (if known)	Neme of Patentee or Applicant of Cited Document	Dete of Publication of Cited Document MM-DD-YYYY		
	1	5532241			July 2, 1996		
	2	6476035			November 5, 2002		
	3	5002948			March 26, 1991		
				.70 1-71-0	ılı		
				_			

				FORI	EIGN PATENT DOCUME	NTS		
		Foreign Patent Document		nent		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Exeminer Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevent Figures Appear	T⁰
600000000000000000000000000000000000000		₩	~~2004054972 ~		Boettcher Herming		000000000000000000000000000000000000000	000000000000000000000000000000000000000
-	5	EP	0648767		Merck Patent GmbH	April 19, 1995		Equv to cite 1
	6	wo	9905140		Mikkelsen Ivan	February 4, 1999		Equv to cite 2
		- WO	02083666		Boettcher Henning	October 24, 2002		***************************************
	8	EP	0376607		Lundbeck & CO AS H	July 4, 1990		Equv to cite 3

Examiner Signature	/Noble Jarrell/	Date Considered	01/07/2008	
-----------------------	-----------------	--------------------	------------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individuel case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent end Tredemark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Petents, P.O. Box 1450, Alexendria, VA 22313-1450.

¹ Unique citation designetion number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols es indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check merk here if English language Translation is attached. Number refers to English language corresponding family member.

10/560734

IAPO REC'OPCTIPTO 15 DEC 2009

Pleese type a plus sign (+) inside this box	+
---	---

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Petent end Tredemark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Petent end Tredemark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to e collection of information unless it contains e valid OMB control number

Substitute fo	r form 1449A/PTC)		Complete if Known		
INICOD	MARTION	DIC		Application Number	PCT/EP2004/005547	
			CLOSURE	Filing Date	May 24, 2005	
STATE	EMENT B	Y AI	PPLICANT	First Named Inventor	Timo HEINRICH et al.	
				Group Art Unit	Unassigned	
(u	se as many she	ets as	necessary)	Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	MERCK-3099	

,	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2			
		Hewitt, Nicola J. et al. "Studies comparing in vivo: in vitro metabolism of three pharmaceutical compounds in rats, dogs, monkeys, and humans 'by! Using cryopreserved hopstocytes misrocomes, and collegen gel immebilized hopetocytes cultures" DRUG				
		METABOLISM AND DISPOSITION, 29(7), 1042-1050 CODEN: DMDSAI; ISSN: 0090-9556, 2001, XP002291527.				
		·				

Examiner /Noble Jarrell/ Signature	Date Considered	01/07/2008
------------------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to epplicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademerk Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandrie, VA 22313-1450.

¹ Unique citation designetion number. ² Applicant is to place e check mark here if English language Translation is attached.